A Phase 3 interventional study of Avatrombopag and Placebo in Immune Thrombocytopenia, sponsored by Sobi, Inc.. Completed at 62 sites in 9 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Sobi, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 5 under way, 2 of them phase 3. avatrombopag · Purpura, Thrombocytopenic, Idiopathic.
Among the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 4th largest by enrollment, is one of 4 that started in 2021, is one of 6 in phase 3, and was the 8th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →5 of the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 2 countries. Recruiting first, the newest first:
Al-Mustansiriyah University · Sites in Iraq
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 6–18
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China
Ages 18+
Ostfold Hospital Trust
Ages 18+
By country, each count listing its studies:
avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 7 · Phase 4 2
First in 2007; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 53 across the 16 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 16 have an industry lead sponsor. The 5 most frequent:
This study is registered under Sobi, Inc., one of the names counted as Swedish Orphan Biovitrum. Under that name alone:
Sobi, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Swedish Orphan Biovitrum has 5 studies filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Phase 3b Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for ≥6 Months
Subjects will be randomized in to blinded therapy of avatrombopag or placebo in a 3:1 ratio for a period of 12 weeks. Subjects who complete the 12 week treatment period and are eligible may continue to the open label extension phase which will last 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study is 3:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 12 weeks
Drug: Avatrombopag
Study is 3:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 12 weeks
Drug: Placebo
Investigational product administered orally for up to 2 years.
Drug: Avatrombopag
Oral avatrombopag tablet or sprinkle capsule
Also known as: Doptelet
Placebo comparator tablet or sprinkle capsule
Durable Platelet Response
The proportion of subjects achieving at least 6 out of 8 weekly platelet counts ≥50×10\^9/L during the last 8 weeks of the 12 week Treatment Period in the Core Phase, in the absence of rescue medication
Time frame: Last 8 weeks of 12 week treatment regimen
Alternative Primary: Platelet Response
The proportion of subjects for whom at least 2 consecutive platelet assessments are ≥50×10\^9/L over the 12 weeks of treatment in the Core Phase in the absence of rescue medication.
Time frame: 12 weeks of treatment
Percentage of Weeks Platelet Count ≥50×10^9/L
The percentage of weeks subjects have a platelet count ≥50×10\^9/L during 12 weeks of treatment in the Core Phase, in the absence of rescue therapy.
Time frame: 12 weeks of treatment
Platelet Response at Day 8
The proportion of subjects with a platelet count ≥50×10\^9/L at day 8, in the absence of rescue therapy.
Time frame: Day 8
Percentage of Weeks Platelet Count Between ≥50×10^9/L and ≤150×10^9/L
The percentage of weeks subjects have a platelet count between ≥50×10\^9/L and ≤150×10\^9/L, during 12 weeks of treatment in the Core Phase, in the absence of rescue therapy.
Time frame: 12 weeks of treatment
Rescue Medications
The proportion of subjects who require rescue medications during 12 weeks of treatment in the Core Phase of the study.
Time frame: 12 weeks of treatment
Incidence of Any Bleeding Event (WHO Grade 1-4)
Overall incidence of bleeding events associated with ITP measured using the WHO Bleeding Scale (Grade 1-4).
Time frame: 12 weeks of treatment
| Milestone | Experimental: Avatrombopag Double Blind | Placebo Comparator:Placebo Double Blind | Avatrombopag Open Label Extension |
|---|---|---|---|
| Started | 54 | 21 | 0 |
| Completed | 44 | 1 | 0 |
| Not completed | 10 | 20 | 0 |
| Withdrew: Adverse event | 2 | 1 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 |
| Withdrew: Lack of efficacy | 7 | 18 | 0 |
| Milestone | Experimental: Avatrombopag Double Blind | Placebo Comparator:Placebo Double Blind | Avatrombopag Open Label Extension |
|---|---|---|---|
| Started | 0 | 0 | 73 |
| Completed | 0 | 0 | 49 |
| Not completed | 0 | 0 | 24 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 |
| Withdrew: Subject noncompliance | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 5 |
| Withdrew: Sponsor request | 0 | 0 | 6 |
| Withdrew: Lack of efficacy | 0 | 0 | 9 |
The proportion of subjects achieving at least 6 out of 8 weekly platelet counts ≥50×10\^9/L during the last 8 weeks of the 12 week Treatment Period in the Core Phase, in the absence of rescue medication
| Participants | Experimental: Avatrombopag | Placebo Comparator:Placebo |
|---|---|---|
| Durable Platelet Response | 15 | 0 |
The proportion of subjects for whom at least 2 consecutive platelet assessments are ≥50×10\^9/L over the 12 weeks of treatment in the Core Phase in the absence of rescue medication.
| Participants | Experimental: Avatrombopag | Placebo Comparator:Placebo |
|---|---|---|
| Alternative Primary: Platelet Response | 44 | 0 |
The percentage of weeks subjects have a platelet count ≥50×10\^9/L during 12 weeks of treatment in the Core Phase, in the absence of rescue therapy.
| percentage of weeks | Experimental: Avatrombopag | Placebo Comparator:Placebo |
|---|---|---|
| Percentage of Weeks Platelet Count ≥50×10^9/L | 48.9 ± 25.22 | 1.2 ± 3.92 |
The proportion of subjects with a platelet count ≥50×10\^9/L at day 8, in the absence of rescue therapy.
| Participants | Experimental: Avatrombopag | Placebo Comparator:Placebo |
|---|---|---|
| Platelet Response at Day 8 | 30 | 0 |
The percentage of weeks subjects have a platelet count between ≥50×10\^9/L and ≤150×10\^9/L, during 12 weeks of treatment in the Core Phase, in the absence of rescue therapy.
| percentage of weeks | Experimental: Avatrombopag | Placebo Comparator:Placebo |
|---|---|---|
| Percentage of Weeks Platelet Count Between ≥50×10^9/L and ≤150×10^9/L | 29.2 ± 19.64 | 1.2 ± 3.92 |
The proportion of subjects who require rescue medications during 12 weeks of treatment in the Core Phase of the study.
| Participants | Experimental: Avatrombopag | Placebo Comparator:Placebo |
|---|---|---|
| Rescue Medications | 4 | 9 |
Overall incidence of bleeding events associated with ITP measured using the WHO Bleeding Scale (Grade 1-4).
| Participants | Experimental: Avatrombopag | Placebo Comparator:Placebo |
|---|---|---|
| Incidence of Any Bleeding Event (WHO Grade 1-4) | 45 | 19 |
Collected over Up to 12 weeks (Core Phase) and up to 2 years (Extension Phase). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: Avatrombopag | 0/54 (0%) | 5/54 (9.3%) | 50/54 (92.6%) |
| Placebo Comparator:Placebo | 0/21 (0%) | 1/21 (4.8%) | 16/21 (76.2%) |
| Open Label Extension Phase | 0/73 (0%) | 22/73 (30.1%) | 71/73 (97.3%) |
| Event | Experimental: Avatrombopag | Placebo Comparator:Placebo | Open Label Extension Phase |
|---|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/54 | 0/21 | 4/73 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/54 | 0/21 | 4/73 |
| Mouth HaemorrhageGastrointestinal disorders | 1/54 | 1/21 | 0/73 |
| Skin HaemorrhageSkin and subcutaneous tissue disorders | 0/54 | 1/21 | 0/73 |
| ThrombocytosisBlood and lymphatic system disorders | 1/54 | 0/21 | 2/73 |
| Mucosal HaemorrhageGeneral disorders | 0/54 | 0/21 | 2/73 |
| GastroenteritisInfections and infestations | 0/54 | 0/21 | 2/73 |
| Immune ThrombocytopeniaBlood and lymphatic system disorders | 1/54 | 0/21 | 1/73 |
| Oral PurpuraGastrointestinal disorders | 1/54 | 0/21 | 0/73 |
| Rectal HaemorrhageGastrointestinal disorders | 1/54 | 0/21 | 1/73 |
| Event | Experimental: Avatrombopag | Placebo Comparator:Placebo | Open Label Extension Phase |
|---|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 6/54 | 2/21 | 30/73 |
| PetechiaeSkin and subcutaneous tissue disorders | 14/54 | 6/21 | 9/73 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/54 | 0/21 | 20/73 |
| PyrexiaGeneral disorders | 9/54 | 0/21 | 18/73 |
| HeadacheNervous system disorders | 10/54 | 4/21 | 17/73 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 12/54 | 4/21 | 17/73 |
| EcchymosisSkin and subcutaneous tissue disorders | 10/54 | 1/21 | 9/73 |
| NasopharyngitisInfections and infestations | 4/54 | 0/21 | 13/73 |
| DiarrhoeaGastrointestinal disorders | 4/54 | 0/21 | 12/73 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 7/54 | 0/21 | 12/73 |
| Age, Continuous(years) | Experimental: Avatrombopag | Placebo Comparator:Placebo | Total |
|---|---|---|---|
| Mean | 8.9 ± 4.36 | 9.9 ± 4.13 | 9.2 ± 4.29 |
| Sex: Female, Male(Participants) | Experimental: Avatrombopag | Placebo Comparator:Placebo | Total |
|---|---|---|---|
| Female | 24 | 12 | 36 |
| Male | 30 | 9 | 39 |
| Ethnicity (NIH/OMB)(Participants) | Experimental: Avatrombopag | Placebo Comparator:Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 5 |
| Not Hispanic or Latino | 50 | 15 | 65 |
| Unknown or Not Reported | 1 | 4 | 5 |
| Race (NIH/OMB)(Participants) | Experimental: Avatrombopag | Placebo Comparator:Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 48 | 15 | 63 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 5 | 8 |
| Region of Enrollment(participants) | Experimental: Avatrombopag | Placebo Comparator:Placebo | Total |
|---|---|---|---|
| Turkey | 20 | 9 | 29 |
| Hungary | 4 | 1 | 5 |
| United States | 8 | 5 | 13 |
| Ukraine | 2 | 0 | 2 |
| Poland | 3 | 1 | 4 |
| United Kingdom | 11 | 2 | 13 |
| France | 0 | 1 | 1 |
| Germany | 2 | 1 | 3 |
| Russia | 4 | 1 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2021 to primary completion in Nov 2023, 32 months.
Results were first posted in Jan 2025, 1 year 2 months after primary completion.
Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 32 months is above that.
Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avatrombopag
Purpura, Thrombocytopenic, Idiopathic →